Compare TXT & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXT | INCY |
|---|---|---|
| Founded | 1923 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 17.0B |
| IPO Year | 1994 | 1994 |
| Metric | TXT | INCY |
|---|---|---|
| Price | $87.89 | $118.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | $95.18 | ★ $103.52 |
| AVG Volume (30 Days) | 1.7M | ★ 1.8M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | 18.01 | ★ 4173.33 |
| EPS | ★ 2.67 | 1.47 |
| Revenue | ★ $14,799,000,000.00 | $3,394,635,000.00 |
| Revenue This Year | $5.87 | $10.44 |
| Revenue Next Year | $4.54 | $10.99 |
| P/E Ratio | ★ $33.13 | $81.50 |
| Revenue Growth | 8.01 | ★ 13.67 |
| 52 Week Low | $76.93 | $77.69 |
| 52 Week High | $101.57 | $132.60 |
| Indicator | TXT | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 53.59 |
| Support Level | $86.84 | $93.60 |
| Resistance Level | $93.29 | $119.29 |
| Average True Range (ATR) | 2.66 | 4.31 |
| MACD | -0.28 | -0.64 |
| Stochastic Oscillator | 33.01 | 25.07 |
Textron is a conglomerate that designs, manufactures, and services a range of specialty aircraft including small jets, propeller-driven airplanes, helicopters, and tilt-rotor aircraft. Textron Aviation manufactures and services Cessna and Beechcraft planes. Bell is a helicopter and tilt-rotor manufacturer and servicer for both commercial and military customers. Textron Systems produces uncrewed aircraft and armored vehicles for the military market as well as aircraft simulators and training for the commercial and military markets. Textron Industrial houses the Kautex business, which manufactures plastic fuel tanks for conventional and hybrid motor vehicles, and other subsidiaries that produce specialized vehicles such as golf carts and all-terrain vehicles.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.